Our company was founded on the idea that the research and development of innovative medicines could be accelerated. Within a decade, we discovered and secured global approvals for two breakthrough medicines and assembled a promising pipeline of investigational therapies.

Today, we are bolder and more ambitious than ever before in our effort to improve and extend the lives of many more patients with serious diseases.

A look inside our labs

Our scientists merge expertise in bioinformatics, structural and cell biology, and world-class drug design capabilities to advance our discovery portfolio. Our approach enables us to rapidly identify compelling disease targets and design innovative therapies that treat root causes of disease.

The result is a robust and diverse portfolio of clinical- and research-stage programs in allergy/inflammation and oncology/hematology. With a steadfast commitment to scientific excellence and to patients, we aim to rapidly and unequivocally change the face of medicine.

Meet our Scientists

Stella (Yunxing) //

Stella (Yunxing) Li: Senior Scientist I, Biophysics

My path

I obtained my B.S. in Physics from Peking University and my Ph.D. in Biophysics from Cornell University (Richard A. Cerione’s lab). My graduate research was focused on using small molecule chemistry to block bioenergetic and metabolic requirements of cancer cell proliferation utilizing structural biology and biophysics approaches.

My experience

After I graduated from Cornell, I moved to Boston to join a computational drug discovery startup company. It was a tremendous learning experience, and I was able to utilize my structural biology skills to contribute to projects that made it to clinical programs. It was here that I was able to develop strong expertise in developing Surface Plasmon Resonance (SPR) assays to study a variety of targets. When I saw that Blueprint Medicines was looking to build out its Biophysics team with its first hire, I knew it was the perfect opportunity for me to grow and learn with such talented and passionate team.

My biggest achievement

During my time at the startup company, I was able to achieve the first co-crystal structure of the candidate compound while bound to its target. This enabled the R&D programs to move forward and shortly afterwards, the compound progressed to clinical trials. It was extremely exciting and rewarding to be a key contributor on a project that may one day be used in patients.

My Blueprint Medicines

I joined Blueprint because of the talented team, the amazing culture and the opportunity to make a true impact for our patients.

Tyler Rouskin-Faust: Senior Scientist II, Biology

My path

I received my B.S. in Biology from the University of Missouri in 2009. For my graduate work, I studied in the lab of Dr. Alan Frankel at UCSF, obtaining a Ph.D. in 2016. Finally, I was a post-doctoral fellow in the lab of Dr. Eric Fischer at Dana-Farber Cancer Institute until 2020.

My experience

My doctoral and post-doctoral studies were focused on aspects of protein degradation. I learned that Blueprint was entering into targeted protein degradation, and I was excited about the opportunity of joining and helping build a nascent effort at a company with a strong track record of bringing medicines to patients.

My biggest achievement

Coming into my postdoc, I had no structural biology experience but wanted to have a better understanding of the discipline. Over my three and a half years of training at Dana-Farber, several colleagues and I were able to solve the structure of an important protein-small molecule complex, which demonstrated that molecular glue degraders (MGD) were more common than the research community anticipated. On a personal level, this achievement also reinforced the idea that with focused effort and learning, daunting new challenges can always be overcome.

My Blueprint Medicines

I joined Blueprint because of the intense commitment to and record of success in bringing targeted medicines to patients in need.

Ludivine Moine: Senior Scientist II, Medicinal Chemistry

My path

I earned a chemical engineering degree from CPE Lyon, France and a M.Sc. in organic chemistry at the University of Montreal, Canada.

My experience

I worked in a big pharma in oncology for many years using different modalities, but I never worked with kinases. I wanted to work for a precision medicine company that specialized in this area and is fully dedicated to discovery. Blueprint Medicines naturally fit the bill.

I was also attracted to Blueprint by the company’s values and its focus on quickly delivering life-changing therapies, and I saw an amazing opportunity for growth and no glass ceiling.

My biggest achievement

I recently contributed to the design and synthesis of multiple research candidates during the COVID-19 pandemic. These efforts offer an opportunity to potentially benefit more patients who harbor specific mutations by targeting the underlying genetic drivers of their disease.

My Blueprint Medicines

Blueprint is a pioneer in precision medicine, and I wanted to learn from the inside how the company has been able to provide innovative therapies to patients in record time. Our core values also resonate with me, and I specifically enjoy how deeply Blueprint invests in discovery and selects targets that may make the most and fastest impact on patients’ lives. Lastly, the collaborative, dynamic, diverse and empowering environment has been another big factor. I believe I can accomplish anything here, and I get the full support of my team to be the best version of myself.

Dean Zhang: Director, Biology Drug Discovery & Targeted Protein Degradation

My path

I was trained as a biochemist and chemical biologist in Dr. Peter Tonge’s group at Stony Brook University. During my five years of Ph.D. training, I tried to understand how drug molecules interact with their protein targets, and how this interaction quantitively translates into drug efficacy.

My experience

After my Ph.D., I joined a pharmaceutical company as a biochemist. There, I was exposed to many different drug discovery projects and learned how to best use my biochemistry background to help discover novel drug molecules. A couple of years in, just when I started doubting if I will ever see a drug that I’ve worked on make it to patients, a biochemist position opened at Blueprint Medicines. I said to myself that this is a rare opportunity where I can work in one of the best small molecule drug discovery organizations, and it might be my best shot to ever deliver a drug to patients. So, I applied and joined.

My biggest achievement

I feel incredibly lucky to be able to apply my background to do a job that’s extremely meaningful and super exciting. It’s already quite an achievement to equip yourself with deep knowledge in any scientific area, but it takes a lot of hard work, perseverance, bravery and more to continue down this road of science and eventually use this knowledge to do a job as meaningful as helping save people’s lives. It sounds like a dream come true because it is a dream that came true.

My Blueprint Medicines

I joined Blueprint because the company stays true to science and has found a way to do drug discovery very efficiently. As a drug discovery scientist, I’ve always dreamt of developing medicines that can impact people’s lives, and Blueprint is the place where I can not only realize this goal, but also do it quickly and many times over.

Stella (Yunxing)

When we think about research innovation at scale at Blueprint, it begins with our talent. Our team combines a deep expertise in the basic science that underpins modern drug discovery, with extensive experience in the applied and translational sciences behind science-led nonclinical development. This enables us to take advantage of our integrated research platform and create transformative new medicines for patients.

Percy Carter, MBA, Ph.D., Chief Science Officer

Scientific Advisory Board

Our Scientific Advisory Board provides their renowned expertise to provide guidance on our scientific approach and help shape our portfolio of innovative medicines.

George Demetri, M.D. (Chair)

Professor of Medicine, Harvard Medical School

Brian Druker, M.D.*

Chief Executive Officer, Oregon Health & Science University Knight Cancer Institute, and JELD-WEN Chair of Leukemia Research

Mark Goldberg, M.D.

Lecturer in Medicine, Harvard Medical School and Faculty Member, Hematology Division, Brigham and Women’s Hospital

Scott Lowe, Ph.D.*

Investigator, Howard Hughes Medical Institute and Chair, Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center

Nicholas Lydon, Ph.D.*

Scientific Founder, Blueprint Medicines

Charles L. Sawyers, M.D.*

Director, Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center and Investigator, Howard Hughes Medical Institute

*Scientific Founder of Blueprint Medicines